Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Azvudine is a potent nucleoside Reverse Transcriptase inhibitor (NRTI), with Antiviral activity on HIV, HBV and HCV. Azvudine inhibits NRTI-resistant viral strains. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM).
Description | Azvudine is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine inhibits NRTI-resistant viral strains. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). |
Targets&IC50 | HIV-2:0.025 nM(EC50), HIV-1:0.03 to 6.92 Nm(EC50) |
In vitro | Azvudine is sensitive to NRTIs-resistant strain HIV-174V, PIs-resistant strains HIV-1L10R/M46I/L63P/V82T/I84V and HIV-1RF V82F/184V, and FIs-resistant strain pNL4-3 gp41 (36G) V38A/N42T. The EC50 values of Azvudine against these resistant strains are 0.11, 0.14, 0.37 and 0.36 nM respectively[1]. Azvudine displays strong inhibition on wild-type HIV-1IIIB and HIV-1RF with an EC50 ranging from 30 to 110 pM. The EC50 values of Azvudine against HIV-1KM018, HIV-1TC-1 and HIV-1WAN T69N are 6.92, 0.34 and 0.45 nM, respectively. |
Synonyms | RO-0622, FNC |
Molecular Weight | 286.22 |
Formula | C9H11FN6O4 |
CAS No. | 1011529-10-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 5.2 mg/ml (18.17 mM)
H2O: 50 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Azvudine 1011529-10-4 Microbiology/Virology Proteases/Proteasome HBV HIV Protease Reverse Transcriptase HCV Protease resistant Human immunodeficiency virus NRTI RO 0622 inhibit mutation Inhibitor RO-0622 HCV Hepatitis C virus Hepatitis B virus HIV FNC analogue RO0622 inhibitor